Author

Michael Scharville

Observed name: M. Scharville

Institution: Arcus Biosciences (United States)

Observed institution: Arcus Biosciences (United States)

OpenAlex ID: A5060729215

ARC-4 study: Efficacy and safety of AB928 plus carboplatin, pemetrexed and a PD-1 antibody in participants with metastatic non-small cell lung cancer (mNSCLC).

2020 · Alexander I. Spira, Paul R. Conkling, et al. · Journal of Clinical Oncology · 12

ARC-12: Phase 1/1b Study to Evaluate Safety and Tolerability of AB308 + Zimberelimab (AB122) in Advanced Malignancies

2021 · Sikander Ailawadhi, Paul Foster, et al. · Blood · 1

1309P ARC-4: Efficacy and safety of AB928 plus carboplatin, pemetrexed and a PD-1 antibody in participants with metastatic non-small cell lung cancer (mNSCLC)

2020 · A. Spira, P. Conkling, et al. · Annals of Oncology · 1

1028TiP ARC-12: Phase I/Ib dose escalation and dose expansion study to evaluate the safety and tolerability of AB308 + zimberelimab (AB122) in advanced malignancies

2021 · J.A. Call, M.A. Mckean, et al. · Annals of Oncology

Works count: 4

Citation count: 14

H-index: 1

I10-index: 1